US pharma giant Eli Lilly has welcomed back Nobel Prize-winning chemist Carolyn R Bertozzi to its board of directors, effective December 8, 2025. Bertozzi, who previously served on the board from 2017 to 2021, will join the Science and Technology and Ethics and Compliance committees.

Her return to Lilly comes at a time when the company is pushing forward on cutting-edge therapies in oncology and immunology, areas where Bertozzi’s pioneering work on targeted medicines is expected to provide critical insight.

"On behalf of Lilly and the entire board, I would like to welcome Carolyn back to Lilly," said David A. Ricks, Lilly chair and CEO.

"Carolyn is a Nobel Prize-winning chemist whose work has fundamentally changed how we think about developing targeted medicines, particularly in cancer. As we continue to pioneer new approaches in oncology and immunology, her perspective will be invaluable. We're fortunate to have her back as we work to deliver more breakthrough medicines to patients."

Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute. She is also an elected member of the National Academy of Medicine, National Academy of Sciences, and the American Academy of Arts and Sciences.